Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service colorectal resection cases in West Virginia: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 430 | 36% |
| 2020 | 2 | 378 | 41% |
| 2021 | 2 | 315 | 46% |
| 2022 | 0 | 325 | 50% |
| 2023 | 1 | 307 | 55% |
| 2024 | 0 | 265 | 58% |
| 2025 from claims | – | 221 178–259 | 59% |
| 2026 forecast | – | 216 169–271 | 60% |
| 2027 forecast | – | 212 157–280 | 61% |
| 2028 forecast | – | 207 147–286 | 62% |
| 2029 forecast | – | 203 138–291 | 63% |
| 2030 forecast | – | 199 130–295 | 64% |
Laparoscopic and open colectomy and proctectomy; stapler, energy, and robotics call point. Professional codes (what the surgeon bills): CPT 44204, 44205, 44207, 44140, 44145, 44160, 45395, 45397; the hospital bills MS-DRG 329, 330, 331.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 15 | 3,636−5.1%/yr | −5.1%/yr | 1.7 | 0% | 3,880 in 2030+1.1%/yr |
| Florida | 14 | 3,627−6.3%/yr | −6.3%/yr | 1.7 | 0% | 3,630 in 20300%/yr |
| North Carolina | 8 | 1,589−6.5%/yr | −6.5%/yr | 1.6 | 0% | 1,360 in 2030−2.6%/yr |
| Virginia | 8 | 1,510−4.9%/yr | −4.9%/yr | 1.5 | 0% | 1,480 in 2030−0.3%/yr |
| Georgia | 9 | 1,488−6.4%/yr | −6.4%/yr | 1.8 | 0% | 1,450 in 2030−0.4%/yr |
| Tennessee | 8 | 1,264−5.6%/yr | −5.6%/yr | 1.8 | 0% | 1,230 in 2030−0.4%/yr |
| Maryland | 9 | 1,152−4.6%/yr | −4.6%/yr | 1.3 | 0% | 1,300 in 2030+2.1%/yr |
| South Carolina | 6 | 1,082−4.9%/yr | −4.9%/yr | 1.6 | 0% | 1,180 in 2030+1.5%/yr |
| Oklahoma | 7 | 875−4%/yr | −4%/yr | 1.8 | 0% | 740 in 2030−2.7%/yr |
| Kentucky | 1 | 825−7.8%/yr | −7.8%/yr | 1.8 | 0% | 700 in 2030−2.7%/yr |
| Alabama | 7 | 775−8.2%/yr | −8.2%/yr | 1.8 | 0% | 760 in 2030−0.3%/yr |
| Louisiana | 3 | 766−7.5%/yr | −7.5%/yr | 1.9 | 0% | 690 in 2030−1.6%/yr |
| Mississippi | 5 | 704−8.2%/yr | −8.2%/yr | 1.9 | 0% | 680 in 2030−0.7%/yr |
| Arkansas | 3 | 698−6%/yr | −6%/yr | 1.9 | 0% | 680 in 2030−0.3%/yr |
| Delaware | 2 | 264−6.1%/yr | −6.1%/yr | 1.6 | 0% | 340 in 2030+4.1%/yr |
| District of Columbia | 1 | 196−6.3%/yr | −6.3%/yr | 3.2 | 0% | 170 in 2030−2.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 8 | 821−8.3%/yr | −8.3%/yr | 4.20.7× | 0% | 620 in 2030−4.5%/yr |
| Cholecystectomy & appendectomy | 19 | 820−11%/yr | −11%/yr | 4.00.9× | 0% | 720 in 2030−2.2%/yr |
| Antireflux & hiatal hernia surgery | 2 | 134−13%/yr | −13%/yr | 0.60.8× | 0% | 100 in 2030−5.2%/yr |
Colorectal resection in every state, and its device makers · Every procedure market in West Virginia · Every state · Compare with Texas
Intuitive Surgical leads with 95% of company spending on these surgeons in 2025, +6 pts on 2024.
In 2025, 3 companies reported engagement with West Virginia’s surgeons worth $30K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 14 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.